EGFR and adenocarcinoma: In addition to this, in R26-AKT1E17K mice lung tumors appears with longer latency and lower incidence compared with mice expressing mutant Egfr (3–4 weeks from the activation of the oncogene) [52,53], Pik3caH1047R (12–60 weeks) [54] or KrasG12D (in which the hyperplastic lesions progress to adenoma by 6 weeks, and less frequently to adenocarcinoma after 15 weeks of age) [38,55,56].